CD163 and malignant colon neoplasm: To determine the level of expression of the targets of the combination immunotherapy and understand its potential relevance to colon cancer treatment, primary and metastatic colon carcinoma tissue microarrays (TMAs) were stained with trichrome, biotinylated NC410, and antibodies directed against PD-L1 or CD163.